The text starts here.

News Release

FOR IMMEDIATE RELEASE
September 12, 2005

NOTICE CONCERNING THE CHANGE OF THE DISTRIBUTION COMPANY FROM AVENTIS PHARMA TO EISAI FOR “ACTONEL(R) 2.5 MG TABLETS” OF AJINOMOTO

Ajinomoto Co., Inc.
Aventis Pharma Ltd.
Eisai Co., Ltd.

Aventis Pharma Ltd., part of the sanofi-aventis Group (President: Philippe Fauchet, Headquarters: Tokyo), Eisai Co., Ltd. (President: Haruo Naito, Headquarters: Tokyo) and Ajinomoto Co., Inc. (President: Norio Yamaguchi, Headquarters: Tokyo) announced today the change of the distribution company for osteoporosis treatment Actonel(R) (generic name: risedronate sodium) for which Ajinomoto has the marketing approval rights in Japan, from Aventis Pharma to Eisai, starting October 1, 2005.

Actonel(R) is the only bisphosphonate agent proven by large-scale clinical trials to reduce the frequency of clinical fractures of the vertebrae and other bones after just six months of administration. In addition, it is also the only such medication confirmed as effective by a large-scale clinical trial focused on evaluation of femoral neck fracture frequency. Since its initial launch in 2000, Actonel(R) has received approval in 92 countries globally.



Contacts:

Ajinomoto Co., Inc.    Sales & Marketing Section   Pharmaceutical Department
Tel : 03-5250-8131
Aventis Pharma Ltd.    Media Relations Communication
Tel : 03-6301-4148
Eisai Co., Ltd.    Corporate Communications Department
Tel : 03-3817-5120